Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals insider Parikh Asit sells 40,000 shares and moves them to a spouse‑benefit trust, signaling a strategic wealth‑management move rather than a cash exit.

Insider buying by Phathom’s chief accountant shows cautious optimism: Breedlove’s recent RSU and PSU purchases hint at confidence amid volatile stock and a negative P/E.

Insider buy by Phathom owner Parikh Asit at $10.30 shows confidence that the drug‑maker is undervalued, but the trade is small and lacks market buzz, so investors should watch for new clinical or partnership data before betting on a rebound.